{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T11:27:20Z","timestamp":1794396440440,"version":"4.9.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010685.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T00:00:00Z","timestamp":1503619200000}}],"reference-count":142,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T00:00:00Z","timestamp":1503619200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T00:00:00Z","timestamp":1503619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010685.pub3","type":"journal-article","created":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T08:21:18Z","timestamp":1503649278000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation"],"prefix":"10.1002","volume":"2017","author":[{"given":"Frank","family":"Peinemann","sequence":"first","affiliation":[{"name":"Children's Hospital, University of Cologne; Pediatric Oncology and Hematology; Kerpener Str. 62 Cologne Germany 50937"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira C","family":"van Dalen","sequence":"additional","affiliation":[{"name":"Emma Children's Hospital\/Academic Medical Center; Department of Paediatric Oncology; PO Box 22660 (room H4-139) Amsterdam Netherlands 1100 DD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Enk","sequence":"additional","affiliation":[{"name":"c\/o Cochrane Childhood Cancer; Amsterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Berthold","sequence":"additional","affiliation":[{"name":"Children's Hospital, University of Cologne; Pediatric Oncology and Hematology; Kerpener Str. 62 Cologne Germany 50937"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,8,25]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD010685.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0360-3016(02)04506-6","article-title":"Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study","volume":"56","author":"Haas-Kogan","year":"2003","journal-title":"International Journal of Radiation Oncology Biology Physics"},{"issue":"9","key":"10.1002\/14651858.CD010685.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.2000.18.9.1888","article-title":"Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: A Children's Cancer Group study","volume":"18","author":"Maris","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD010685.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1007-13. The pu","DOI":"10.1200\/JCO.2007.13.8925","article-title":"Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study","volume":"27","author":"Matthay","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10.1002\/14651858.CD010685.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJM199910143411601","article-title":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group","volume":"341","author":"Matthay","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010685.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/pbc.21784","article-title":"Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group","volume":"52","author":"Park","year":"2009","journal-title":"Pediatric Blood and Cancer"},{"issue":"27","key":"10.1002\/14651858.CD010685.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"6474","DOI":"10.1200\/JCO.2005.05.183","article-title":"Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study","volume":"23","author":"Schmidt","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD010685.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1200\/JCO.1997.15.11.3330","article-title":"Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer","volume":"15","author":"Adamson","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD010685.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/pbc.21011","article-title":"A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study","volume":"49","author":"Adamson","year":"2007","journal-title":"Pediatric Blood and Cancer"},{"issue":"21","key":"10.1002\/14651858.CD010685.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1182\/blood.V122.21.3411.3411","article-title":"High-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma : Results of Turkish pediatric oncology group-neuroblastoma 2003 (TPOG-NBL 2003) protocol. 55th Annual Meeting of the American Society of Hematology, ASH 2013 New Orleans, LA United States","volume":"122","author":"Aksoylar","year":"2013","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0010|cit10","first-page":"69-74, 78","article-title":"Current phase III clinical trials investigating pediatric cancers","volume":"19","author":"Anderson","year":"2005","journal-title":"Oncology"},{"issue":"2","key":"10.1002\/14651858.CD010685.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3109\/07853899609092941","article-title":"Autologous stem cell transplantation in solid tumours of childhood","volume":"28","author":"Atra","year":"1996","journal-title":"Annals of Medicine"},{"issue":"5 suppl","key":"10.1002\/14651858.CD010685.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"abstr 10069","DOI":"10.1200\/jco.2014.32.15_suppl.10069","article-title":"Evaluation of resources used during care of children with high-risk neuroblastoma (HR NBL) via merging of cooperative group trial data and administrative data. 2014 ASCO Annual Meeting","volume":"32","author":"Bagatell","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s11096-011-9519-9","article-title":"Practical implications for the administration of 13-cis retinoic acid in pediatric oncology","volume":"33","author":"Bauters","year":"2011","journal-title":"International Journal of Clinical Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD010685.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1517\/14656566.5.1.71","article-title":"A comparison of current neuroblastoma chemotherapeutics","volume":"5","author":"Castel","year":"2004","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/pbc.20705","article-title":"Favorable histology, MYCN-amplified 4S neonatal neuroblastoma","volume":"48","author":"Chan","year":"2007","journal-title":"Pediatric Blood and Cancer"},{"issue":"6","key":"10.1002\/14651858.CD010685.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/MPH.0000000000000362","article-title":"Predicting, monitoring, and managing hypercalcemia secondary to 13-cis-retinoic acid therapy in children with high-risk neuroblastoma","volume":"37","author":"Chen","year":"2015","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"6","key":"10.1002\/14651858.CD010685.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/08880010390219858","article-title":"Pneumocystis carinii pneumonia: a late presentation following treatment for stage IV neuroblastoma","volume":"20","author":"Clarke","year":"2003","journal-title":"Pediatric Hematology and Oncology"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/pbc.22052","article-title":"Hypercalcemia and osteoblastic lesions induced by 13-Cis-retinoic acid mimicking relapsed neuroblastoma","volume":"53","author":"Cross","year":"2009","journal-title":"Pediatric Blood and Cancer"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ejca.2008.01.010","article-title":"Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age","volume":"44","author":"Kraker","year":"2008","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub3-BIB0020|cit20","first-page":"437","article-title":"Complete objective response of neuroblastoma to biological treatment","volume":"30","author":"Bella","year":"2009","journal-title":"Neuroendocrinology Letters"},{"issue":"17","key":"10.1002\/14651858.CD010685.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/jnci\/djh268","article-title":"Fenretinide activates a distinct apoptotic pathway","volume":"96","author":"Dmitrovsky","year":"2004","journal-title":"Journal of the National Cancer Institute"},{"issue":"11","key":"10.1002\/14651858.CD010685.pub3-BIB0022|cit22","first-page":"1734","article-title":"Stage 4S neuroblastoma, a disseminated tumor with excellent outcome","volume":"27","author":"Elimam","year":"2006","journal-title":"Saudi Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/mpo.2950200407","article-title":"13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Childrens Cancer Study Group","volume":"20","author":"Finklestein","year":"1992","journal-title":"Medical and Pediatric Oncology"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00280-007-0649-7","article-title":"Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide","volume":"62","author":"Formelli","year":"2008","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD010685.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00280-010-1370-5","article-title":"Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients","volume":"66","author":"Formelli","year":"2010","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"22","key":"10.1002\/14651858.CD010685.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1200\/JCO.2009.25.9119","article-title":"Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report","volume":"28","author":"Fouladi","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0027|cit27","doi-asserted-by":"crossref","unstructured":"French S Dubois SG Horn B Granger M Hawkins R Pass A 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma Pediatric Blood and Cancer 2013 879 84","DOI":"10.1002\/pbc.24351"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0028|cit28","first-page":"311","article-title":"Retinoids in therapy of neuroblastoma","volume":"20","author":"Frgala","year":"2007","journal-title":"Klinicka Onkologie"},{"issue":"6","key":"10.1002\/14651858.CD010685.pub3-BIB0029|cit29","first-page":"2032","article-title":"Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma","volume":"9","author":"Garaventa","year":"2003","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10.1002\/14651858.CD010685.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/pbc.24207","article-title":"Feasibility of a tandem autologous peripheral blood stem cell transplant regimen for high risk neuroblastoma in a cooperative group setting: A Pediatric Oncology Group study: A Report from the Children's Oncology Group","volume":"59","author":"Granger","year":"2012","journal-title":"Pediatric Blood and Cancer"},{"issue":"3","key":"10.1002\/14651858.CD010685.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/BF01405299","article-title":"Hypervitaminosis A as a complication of treatment for neuroblastoma","volume":"26","author":"Grissom","year":"1996","journal-title":"Pediatric Radiology"},{"issue":"2","key":"10.1002\/14651858.CD010685.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mpo.10089","article-title":"Sweet syndrome associated with 13-cis-retinoic acid (isotretinoin) therapy","volume":"40","author":"Gyorfy","year":"2003","journal-title":"Medical Pediatric Oncology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD010685.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"S251","DOI":"10.1016\/j.bbmt.2011.12.138","article-title":"Comparison of autologous hematopoietic stem cell transplantation with and without metaiodobenzylguanidine (MIBG) in patients with high risk neuroblastoma. 2012 BMT Tandem Meetings San Diego, CA United States","volume":"18","author":"Hamidieh","year":"2012","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s00467-004-1775-7","article-title":"Retinoic acid may increase the risk of bone marrow transplant nephropathy","volume":"20","author":"Haysom","year":"2005","journal-title":"Pediatric Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub3-BIB0035|cit35","first-page":"203","article-title":"1st clinical experience with subtoxic vitamin A doses during radiation and cytostatic tumor therapy","volume":"24","author":"Hoefer-Janker","year":"1969","journal-title":"Krebsarzt"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1507\/endocrj.46.Suppl_S113","article-title":"A case of growth failure caused by 13-CIS-retinoic acid administration after bone marrow transplantation for neuroblasoma","volume":"46 Suppl","author":"Inamo","year":"1999","journal-title":"Endocrine Journal"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/pbc.21366","article-title":"Chronic metastatic neuroblastoma","volume":"50","author":"Kazanowska","year":"2008","journal-title":"Pediatric Blood and Cancer"},{"issue":"1-2","key":"10.1002\/14651858.CD010685.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s002800050535","article-title":"Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation","volume":"39","author":"Khan","year":"1996","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"9","key":"10.1002\/14651858.CD010685.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1200\/JCO.2002.06.060","article-title":"Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: Results of the Chicago Pilot II study","volume":"20","author":"Kletzel","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0040|cit40","unstructured":"Kogner P Borgstr\u00f6m P Karpe B Lundell G Hjelm Skog AL Winiarski J Children with high-risk neuroblastoma may be long-term survivors after application of intensified multimodal therapy. 36th Congress of the International Society of Paediatric Oncology, SIOP 2004, Oslo, Norway, Abstract P.C.005 Pediatric Blood and Cancer 2004 400"},{"issue":"9","key":"10.1002\/14651858.CD010685.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1054\/bjoc.2000.1425","article-title":"A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy","volume":"83","author":"Kohler","year":"2000","journal-title":"British Journal of Cancer"},{"issue":"10","key":"10.1002\/14651858.CD010685.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S1470-2045(13)70309-7","article-title":"Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial","volume":"14","author":"Kreissman","year":"2013","journal-title":"Lancet Oncology"},{"issue":"12","key":"10.1002\/14651858.CD010685.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.1994.12.12.2607","article-title":"Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age","volume":"12","author":"Kushner","year":"1994","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10.1002\/14651858.CD010685.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2001.19.22.4189","article-title":"Phase II trial of the anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma","volume":"19","author":"Kushner","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD010685.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/sj.bmt.1703213","article-title":"Topotecan combined with myeloablative does of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults","volume":"28","author":"Kushner","year":"2001","journal-title":"Bone Marrow Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD010685.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/00043426-200307000-00003","article-title":"Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-G(D2) immunotherapy","volume":"25","author":"Kushner","year":"2003","journal-title":"Journal of Pediatric Hematology and Oncology"},{"issue":"6","key":"10.1002\/14651858.CD010685.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/mpo.10273","article-title":"Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience","volume":"41","author":"Kushner","year":"2003","journal-title":"Medical Pediatric Oncology"},{"issue":"7","key":"10.1002\/14651858.CD010685.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"e1016704","DOI":"10.1080\/2162402X.2015.1016704","article-title":"Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: A prospective Phase II study","volume":"4","author":"Kushner","year":"2015","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.18632\/oncotarget.6393","article-title":"Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin","volume":"7","author":"Kushner","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub3-BIB0050|cit50","first-page":"402","article-title":"The siopen-r-net project: building a european network for neuroblastoma treatment (hr-nbl-1\/esiop trial) and research. 36th Congress of the International Society of Paediatric Oncology, SIOP 2004, Oslo, Norway, Abstract P.C.014","volume":"43","author":"Ladenstein","year":"2004","journal-title":"Pediatric Blood and Cancer"},{"issue":"5 suppl","key":"10.1002\/14651858.CD010685.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"abstr 10026","DOI":"10.1200\/jco.2014.32.15_suppl.10026","article-title":"Immunotherapy (IT) with ch14.18\/CHO for high-risk neuroblastoma: First results from the randomised HR-NBL1\/SIOPEN trial. 2014 ASCO Annual Meeting","volume":"32","author":"Ladenstein","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD010685.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/bmt.2010.182","article-title":"Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT","volume":"46","author":"Laskin","year":"2011","journal-title":"Bone Marrow Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD010685.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11060-005-9062-4","article-title":"Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme","volume":"78","author":"Levin","year":"2006","journal-title":"Journal of Neurooncology"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0054|cit54","doi-asserted-by":"crossref","unstructured":"Lie SO Retinoids in the treatment of neuroblastoma. [abstract no: 204 ] European Journal of Cancer 1993 S42","DOI":"10.1016\/0959-8049(93)90826-2"},{"issue":"2","key":"10.1002\/14651858.CD010685.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/pbc.21768","article-title":"Hypercalcemia and 13-cis-retinoic acid in post-consolidation therapy of neuroblastoma","volume":"52","author":"Marabelle","year":"2009","journal-title":"Pediatric Blood and Cancer"},{"issue":"9","key":"10.1002\/14651858.CD010685.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.2000.18.9.1888","article-title":"Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: A Children's Cancer Group study","volume":"18","author":"Maris","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD010685.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10633-008-9132-y","article-title":"Total rod ERG suppression with high dose compassionate Fenretinide usage","volume":"117","author":"Marmor","year":"2008","journal-title":"Documenta Ophthalmologica"},{"issue":"7","key":"10.1002\/14651858.CD010685.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/pbc.22986","article-title":"Treatment of advanced neuroblastoma in children over 1 year of age: The critical role of 131I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen","volume":"56","author":"Mastrangelo","year":"2011","journal-title":"Pediatric Blood and Cancer"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/0959-8049(95)00015-B","article-title":"Role of myeloablative therapy in improved outcome for high risk neuroblastoma: Review of recent Children's Cancer Group results","volume":"31A","author":"Matthay","year":"1995","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0060|cit60","first-page":"89","article-title":"Current results with myeloablative therapy with hematopoietic support in advanced neuroblastoma","volume":"9","author":"Matthay","year":"1999","journal-title":"Cancer Research Therapy and Control"},{"issue":"9","key":"10.1002\/14651858.CD010685.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1054\/bjoc.2000.1430","article-title":"Is there a role for retinoids to treat minimal residual disease in neuroblastoma?","volume":"83","author":"Matthay","year":"2000","journal-title":"British Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD010685.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/JCO.2005.03.6400","article-title":"Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study","volume":"24","author":"Matthay","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD010685.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/1078-0432.CCR-12-3313","article-title":"Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption","volume":"19","author":"Matthay","year":"2013","journal-title":"Clinical Cancer Research"},{"issue":"11","key":"10.1002\/14651858.CD010685.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/pbc.24643","article-title":"Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed\/refractory neuroblastoma: a report from the new approaches to neuroblastoma therapy (NANT) consortium","volume":"60","author":"Maurer","year":"2013","journal-title":"Pediatric Blood and Cancer"},{"issue":"5 suppl","key":"10.1002\/14651858.CD010685.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"abstr 10071","DOI":"10.1200\/jco.2014.32.15_suppl.10071","article-title":"Fenretinide (4-HPR)\/Lym-X-Sorb (LXS) oral powder plus ketoconazole in patients with high-risk (HR) recurrent or resistant neuroblastoma: A new approach to neuroblastoma therapy (NANT) consortium trial. 2014 ASCO Annual Meeting","volume":"32","author":"Maurer","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD010685.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/jnci\/85.12.939","article-title":"ASCO\/AACR: shared emphases and separate meetings","volume":"85","author":"McCann","year":"1993","journal-title":"Journal of the National Cancer Institute"},{"issue":"7","key":"10.1002\/14651858.CD010685.pub3-BIB0067|cit67","first-page":"521","article-title":"Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7)","volume":"17","author":"Mora","journal-title":"2015"},{"issue":"11","key":"10.1002\/14651858.CD010685.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/pbc.26180","article-title":"Skeletal impact of retinoid therapy in childhood cancer survivors","volume":"63","author":"Mostoufi-Moab","year":"2016","journal-title":"Pediatric Blood & Cancer"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1442-200X.1995.tb03361.x","article-title":"Comprehensive treatment of advanced neuroblastoma involving autologous bone marrow transplant","volume":"37","author":"Mugishima","year":"1995","journal-title":"Acta Paediatrica Japonica"},{"issue":"2","key":"10.1002\/14651858.CD010685.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1442-200X.2008.02544.x","article-title":"Hypercalcemia induced by 13 cis-retinoic acid in patients with neuroblastoma","volume":"50","author":"Mugishima","year":"2008","journal-title":"Pediatrics International"},{"issue":"6","key":"10.1002\/14651858.CD010685.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s004310050631","article-title":"Generalized metaphyseal modification with cone-shaped epiphyses following long-term administration of 13-cis-retinoic acid","volume":"156","author":"Nishimura","year":"1997","journal-title":"European Journal of Pediatrics"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD010685.pub3-BIB0072|cit72","first-page":"140","article-title":"The Turkish pediatric oncology group neuroblastoma 2003 (tpog-nb-2003): treatment results of the high risk group. 40th Annual Conference of the International Society of Paediatric Oncology, SIOP 2008, Berlin, Germany, Abstract D110","volume":"50","author":"Olgun","year":"2008","journal-title":"Pediatric Blood and Cancer"},{"issue":"5 suppl","key":"10.1002\/14651858.CD010685.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"abstr 10044","DOI":"10.1200\/jco.2014.32.15_suppl.10044","article-title":"A comprehensive safety trial of chimeric antibody 14.18 (ch14.18) with GM-CSF, IL-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: A Children's Oncology Group study. 2014 ASCO Annual Meeting","volume":"32","author":"Ozkaynak","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0074|cit74","doi-asserted-by":"crossref","unstructured":"Park JR Villablanca JG Seeger R Shimada H London W Gerbing R Outcome of high risk (HR) stage 3 neuroblastoma (NB) with myeloablative therapy and 13-cis-retinoic acid. Abstracts for the 41th Annual Meeting of the American Society of Clinical Oncology, Orlando,FL, 13-17 May, 2005 [Abstract No. 8503] Annual Meeting Proceedings of the American Society of Clinical Oncology Alexandria American Society of Clinical Oncology 2005 800","DOI":"10.1200\/jco.2005.23.16_suppl.8503"},{"issue":"33","key":"10.1002\/14651858.CD010685.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1200\/JCO.2010.34.3293","article-title":"Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study","volume":"29","author":"Park","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0076|cit76","doi-asserted-by":"crossref","unstructured":"Pearson AD Pinkerton CR Lewis IJ Imeson J Ellershaw C Machin D High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial Lancet Oncology 2008 247 56","DOI":"10.1016\/S1470-2045(08)70069-X"},{"issue":"6","key":"10.1002\/14651858.CD010685.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/pbc.22200","article-title":"Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide","volume":"53","author":"Rayburg","year":"2009","journal-title":"Pediatric Blood and Cancer"},{"issue":"13","key":"10.1002\/14651858.CD010685.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/jnci\/91.13.1099","article-title":"Fenretinide: the death of a tumor cell","volume":"91","author":"Reed","year":"1999","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"10.1002\/14651858.CD010685.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00043426-200103000-00005","article-title":"Detection of minimal residual disease in bone marrow during or after therapy as a prognostic marker for high-risk neuroblastoma","volume":"23","author":"Reynolds","year":"2001","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0080|cit80","doi-asserted-by":"crossref","unstructured":"Richtig E Soyer HP Posch M Mossbacher U Bauer P Teban L Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group Journal of Clinical Oncology 2005 8655 63","DOI":"10.1200\/JCO.2004.00.8128"},{"issue":"2","key":"10.1002\/14651858.CD010685.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/bjc.1982.48","article-title":"Trial of an aromatic retinoid in patients with solid tumours","volume":"45","author":"Rustin","year":"1982","journal-title":"British Journal of Cancer"},{"issue":"7","key":"10.1002\/14651858.CD010685.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/pbc.24173","article-title":"Thiotepa and melphalan based single, tandem, and triple high dose therapy and autologous stem cell transplantation for high risk neuroblastoma","volume":"59","author":"Saarinen-Pihkala","year":"2012","journal-title":"Pediatric Blood and Cancer"},{"issue":"3","key":"10.1002\/14651858.CD010685.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/pbc.24111","article-title":"13-cis-retinoic acid-associated bone marrow edema in neuroblastoma","volume":"59","author":"Sato","year":"2012","journal-title":"Pediatric Blood and Cancer"},{"issue":"24","key":"10.1002\/14651858.CD010685.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2000.18.24.4067","article-title":"Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study","volume":"18","author":"Seeger","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD010685.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1055\/s-2005-836518","article-title":"Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy","volume":"217","author":"Simon","year":"2005","journal-title":"Klinische P\u00e4diatrie"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0086|cit86","unstructured":"Simon T Hero B Handgretinger R Schrappe M Klingebiel T Fruehwald M Anti-GD2-antibody CH14.18 or retinoic acid as consolidation therapy in high-risk neuroblastoma. 43rd Congress of the International Society of Paediatric Oncology, SIOP 2011 Auckland New Zealand Pediatric Blood and Cancer 2011 789"},{"issue":"1","key":"10.1002\/14651858.CD010685.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/pbc.20848","article-title":"Favorable response of intraommaya topotecan for leptomeningeal metastasis of neuroblastoma after intravenous route failure","volume":"50","author":"Sirachainan","year":"2008","journal-title":"Pediatric Blood and Cancer"},{"issue":"1","key":"10.1002\/14651858.CD010685.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/sj.bmt.1705691","article-title":"Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma","volume":"40","author":"Sung","year":"2007","journal-title":"Bone Marrow Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD010685.pub3-BIB0089|cit89","first-page":"770","article-title":"Comprehensive protocol for diagnosis and treatment of childhood neuroblastoma--results of 45 cases","volume":"44","author":"Tang","year":"2006","journal-title":"Zhonghua Er Ke Za Zhi (Chinese Journal of Pediatrics)"},{"issue":"9","key":"10.1002\/14651858.CD010685.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s004670050693","article-title":"Possible association of retinoic acid with bone marrow transplant nephropathy","volume":"13","author":"Turman","year":"1999","journal-title":"Pediatric Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD010685.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/sj.bjc.6603554","article-title":"Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - a study of the United Kingdom Children's Cancer Study Group","volume":"96","author":"Veal","year":"2007","journal-title":"British Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD010685.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/1078-0432.CCR-12-2225","article-title":"Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma","volume":"19","author":"Veal","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0093|cit93","unstructured":"Villablanca JG Avramis VI Khan AA Matthay KK Ramsay NKC Seeger RC Phase I trial of 13-Cis-Retinoic acid (cis-RA) in neuroblastoma patients following bone marrow transplantation (BMT) [abstract] Proceedings of the American Society of Clinical Oncology Alexandria American Society of Clinical Oncology 1992 366, Abstract 1263"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub3-BIB0094|cit94","first-page":"410","article-title":"Hypercalcemia: a dose-limiting toxicity associated with 13-cis-retinoic acid","volume":"15","author":"Villablanca","year":"1993","journal-title":"American Journal of Pediatric Hematology\/Oncology"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1200\/JCO.1995.13.4.894","article-title":"Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation","volume":"13","author":"Villablanca","year":"1995","journal-title":"Journal of Clinical Oncology"},{"issue":"21","key":"10.1002\/14651858.CD010685.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1200\/JCO.2005.03.9271","article-title":"Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709)","volume":"24","author":"Villablanca","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"21","key":"10.1002\/14651858.CD010685.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1158\/1078-0432.CCR-11-0995","article-title":"Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR\/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group","volume":"17","author":"Villablanca","year":"2011","journal-title":"Clincal Cancer Research"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0098|cit98","doi-asserted-by":"crossref","unstructured":"Weitman S Ochoa S Sullivan J Shuster J Winick N Pratt C Pediatric phase II cancer chemotherapy trials: A Pediatric Oncology Group study Journal of Pediatric Hematology\/Oncology 1997 187 91","DOI":"10.1097\/00043426-199705000-00002"},{"issue":"22","key":"10.1002\/14651858.CD010685.pub3-BIB0099|cit99","first-page":"1556","article-title":"Therapeutic experience of childhood stage III neuroblastoma","volume":"90","author":"Ye","year":"2010","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0100|cit100","doi-asserted-by":"crossref","unstructured":"Yu AL Gilman AL Ozkaynak MF London WB Kreissman SG Chen HX Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma New England Journal of Medicine 2010 1324 34","DOI":"10.1056\/NEJMoa0911123"},{"issue":"12","key":"10.1002\/14651858.CD010685.pub3-BIB0101|cit101","first-page":"1931","article-title":"Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid","volume":"2","author":"Yung","year":"1996","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0102|cit102","first-page":"467","article-title":"Therapeutic effects of high dose chemotherapy combined with autologous peripheral blood stem cell transplantation on 18 cases of stage IV neuroblastoma in children","volume":"37","author":"Zhu","year":"2010","journal-title":"Chinese Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0103|cit103","unstructured":"Reynolds CP Villablanca JG Stram DO Harris R Seeger RC Matthay KK 13-CIS-retinoic acid after intensive consolidation therapy for neuroblastoma improves event-free survival: a randomized Children's Cancer Group study. 34th Annual Meeting of the American Society of Clinical Oncology; 16-19 May 1998; Los Angeles, California, USA Proceedings of the American Society of Clinical Oncology Alexandria American Society of Clinical Oncology 1998 2a, Abstract 5"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0104|cit104","unstructured":"Reynolds CP Villablanca JG Gerbing RB Stram DO Seeger RC Matthay KK 13-cis-retinoic acid improves overall survival following myeloablative therapy for high-risk neuroblastoma: a randomized Children's Cancer Group study. 38th Annual Meeting of the American Society of Clinical Oncology; 18-21 May 2002; Orlando, Florida, USA Proceedings of the American Society of Clinical Oncology Alexandria American Society of Clinical Oncology 2002 392a, Abstract 1564"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/3-540-26616-X_7","article-title":"Clinical presentation","volume-title":"Neuroblastoma","author":"Berthold","year":"2005"},{"issue":"1","key":"10.1002\/14651858.CD010685.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1148\/radiol.11101352","article-title":"Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project","volume":"261","author":"Brisse","year":"2011","journal-title":"Radiology"},{"issue":"8","key":"10.1002\/14651858.CD010685.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.1993.11.8.1466","article-title":"Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment","volume":"11","author":"Brodeur","year":"1993","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0108|cit108","unstructured":"Centers of Disease Control and Prevention (CDC) Clinical growth charts. Birth to 36 months: boys length-for-age and weight-for-age percentiles www.cdc.gov\/growthcharts\/data\/set1clinical\/cj41c017.pdf"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0109|cit109","unstructured":"Centers of Disease Control and Prevention Clinical growth charts. 2 to 20 years: boys stature-for-age and weight-for-age percentiles www.cdc.gov\/growthcharts\/data\/set1clinical\/cj41c021.pdf"},{"issue":"36","key":"10.1002\/14651858.CD010685.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1200\/JCO.2014.58.1678","article-title":"When overall survival fails to confirm event-free survival, should the latter be used to set the standard of care?","volume":"32","author":"Cheung","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD010685.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","article-title":"The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report","volume":"27","author":"Cohn","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD010685.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1158\/1078-0432.CCR-11-1409","article-title":"New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome","volume":"18","author":"Cole","year":"2012","journal-title":"Clininical Cancer Research"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0113|cit113","unstructured":"Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40"},{"issue":"3","key":"10.1002\/14651858.CD010685.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0115|cit115","doi-asserted-by":"crossref","unstructured":"Errata Journal of Clinical Oncology 2014 1862 3","DOI":"10.1200\/JCO.2014.57.0382"},{"issue":"1","key":"10.1002\/14651858.CD010685.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pbc.20859","article-title":"Neuroblastoma in adults: Incidence and survival analysis based on SEER data","volume":"49","author":"Esiashvili","year":"2007","journal-title":"Pediatric Blood & Cancer"},{"issue":"2","key":"10.1002\/14651858.CD010685.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G","article-title":"A proposed staging for children with neuroblastoma. Children's Cancer Study Group A","volume":"27","author":"Evans","year":"1971","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0118|cit118","unstructured":"Genetic and Rare Diseases Information Center (GARD) The Office of Rare Diseases Research (ORDR) Neuroblastoma rarediseases.info.nih.gov\/gard\/7185\/neuroblastoma\/resources\/1"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0119|cit119","unstructured":"Goodman MT Gurney JG Smith MA Olshan AF SEER Pediatric Monograph. Sympathetic Nervous System Tumors seer.cancer.gov\/publications\/childhood\/sympathetic.pdf"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0120|cit120","unstructured":"McMaster University (developed by Evidence prime) GRADEpro GDT 2015"},{"issue":"9","key":"10.1002\/14651858.CD010685.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1200\/JCO.2007.12.3349","article-title":"Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97","volume":"26","author":"Hero","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"7414","key":"10.1002\/14651858.CD010685.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0123|cit123","unstructured":"Higgins JPT Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0124|cit124","unstructured":"International Clinical Sciences Support Center (ICSSC) WHO Toxicity Grading Scale for Determining The Severity of Adverse Events www.icssc.org\/Documents\/Resources\/AEManual2003AppendicesFebruary_06_2003%20final.pdf"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0125|cit125","unstructured":"Kremer LCM Van Dalen EC Moher D Caron HN Cochrane Childhood Cancer Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) onlinelibrary.wiley.com\/o\/cochrane\/clabout\/articles\/CHILDCA\/frame.html"},{"issue":"10","key":"10.1002\/14651858.CD010685.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1158\/1078-0432.CCR-11-1939","article-title":"Promising therapeutic targets in neuroblastoma","volume":"18","author":"Matthay","year":"2012","journal-title":"Clinical Cancer Research"},{"issue":"7","key":"10.1002\/14651858.CD010685.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0128|cit128","unstructured":"National Cancer Institute: PDQ\u00ae Neuroblastoma Treatment. Bethesda, MD: National Cancer Institute. Updated 14 April 2017 http:\/\/cancer.gov\/cancertopics\/pdq\/treatment\/neuroblastoma\/HealthProfessional"},{"issue":"24","key":"10.1002\/14651858.CD010685.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0130|cit130","unstructured":"Ratko TA Belinson SE Brown HM Noorani HZ Chopra RD Marbella A Hematopoietic stem-cell transplantation in the pediatric population. AHRQ Comparative Effectiveness Reviews www.ncbi.nlm.nih.gov\/books\/NBK84626\/"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0131|cit131","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"1-2","key":"10.1002\/14651858.CD010685.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0304-3835(03)00108-3","article-title":"Retinoid therapy of high-risk neuroblastoma","volume":"197","author":"Reynolds","year":"2003","journal-title":"Cancer Letters"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0133|cit133","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"2","key":"10.1002\/14651858.CD010685.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jnci\/73.2.405","article-title":"Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas","volume":"73","author":"Shimada","year":"1984","journal-title":"Journal of the National Cancer Institute"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub3-BIB0135|cit135","first-page":"589","article-title":"Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro","volume":"68","author":"Sidell","year":"1982","journal-title":"Journal of the National Cancer Institute"},{"issue":"1","key":"10.1002\/14651858.CD010685.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"21-30","DOI":"10.1016\/0014-4827(83)90184-2","article-title":"Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines","volume":"148","author":"Sidell","year":"1983","journal-title":"Experimental Cell Research"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"10","key":"10.1002\/14651858.CD010685.pub3-BIB0138|cit138","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006301.pub4","article-title":"High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma","author":"Yal\u00e7in","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010685.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1471-2288-12-47","article-title":"Assessment of reporting quality of conference abstracts in sports injury prevention according to CONSORT and STROBE criteria and their subsequent publication rate as full papers","volume":"12","author":"Yoon","year":"2012","journal-title":"BMC Medical Research Methodology"},{"issue":"7","key":"10.1002\/14651858.CD010685.pub3-BIB0140|cit140","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010685","article-title":"Retinoic acid post consolidation therapy for high-risk neuroblastoma","author":"Peinemann","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010685.pub3-BIB0141|cit141","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010685.pub2","article-title":"Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation","author":"Peinemann","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD010685.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1055\/s-0042-101169","article-title":"Retinoic acid for high-risk neuroblastoma patients after autologous stem cell transplantation - Cochrane Review","volume":"228","author":"Peinemann","year":"2016","journal-title":"Klinische Padiatrie"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010685.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T09:17:41Z","timestamp":1692695861000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010685.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Childhood Cancer Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,8,25]]},"references-count":142,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010685.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,25]]}}}